

LETTER TO THE EDITOR

In Patients not Suitable for Generalised Anaesthesia, Surgery for Necrotising Fasciitis under Spinal Anaesthesia should be Considered



This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Date of submission: 21st December 2024

Date of acceptance: 10th January 2025

Dear editor,

We read with interest the article by Faris *et al*¹ about a 54-year-old man who suffered from necrotizing fasciitis secondary to enterococcal infection but, due to severe heart failure and anticoagulation with dabigatran¹, did not undergo resection of the necrosis, which is the gold standard in the treatment of fasciitis², but instead underwent conservative therapy. Despite this strategy, the patient partially recovered at the three-month follow-up with partial detachment of the eschar with underlying healthy granulation tissue and was able to use a wheelchair¹. Some ambiguities should be clarified.

First, we do not agree with the assumption that the fasciitis was caused by dabigatran, as stated in the title of the study¹. So far, there is no evidence that dabigatran itself can directly cause fasciitis. Necrotizing fasciitis is a rare but serious bacterial infection. It can very quickly develop into a life-threatening emergency³. Early symptoms include fever, severe pain and a rapidly spreading infection. People with necrotizing fasciitis require immediate hospital treatment, antibiotics and surgery³.

The second point is that it was not stated how the fasciitis was diagnosed. Was a biopsy or MRI performed on admission? Was the fasciitis diagnosed simply on the basis of the clinical picture on admission, as shown in Figure 1?

The third point is that the underlying pathophysiology of the fasciitis was not clarified. By what route did the patient become infected with enterococci? Did the patient have a history of cuts and scratches, burns and scalds, insect bites, previous surgery or medication injected into the skin? Has he had skin bleeding from the anticoagulant?

The fourth point is that it is not understandable why the surgery for fasciitis was not performed under spinal

anaesthesia⁴. It is also incomprehensible why the anticoagulant effect of dabigatran was not antagonised with Idarucizumab before the operation.

The fifth point is that the indication for dabigatran is unclear. Was the patient on anticoagulation for severe heart failure, atrial fibrillation, deep vein thrombosis or pulmonary embolism? There was also no mention of whether the coagulation parameters on admission indicated that the patient was actually anticoagulated on admission. Was the aPTT prolonged? Was the serum level of dabigatran measured? It is also unclear what the authors mean by the term "coagulopathy". Was the patient over- or under-coagulated? Did he also have an inherited or acquired coagulopathy?

The sixth point is that the cause of the severe heart failure was not specified¹. Was it hypertrophic or dilated cardiomyopathy, myocarditis, coronary artery disease or Takotsubo syndrome? Did the patient have classic cardiovascular risk factors such as hypertension, diabetes, smoking, hyperlipidemia or atrial fibrillation? What was the current medication at the time of admission?

The seventh point is that the reason for the resuscitation was not stated¹. Did the patient require resuscitation for asystole, ventricular fibrillation, heart failure, pulmonary embolism or septic shock? The explanation for CRP is crucial for the interpretation of the course of the disease and the underlying pathophysiology.

In summary, it can be said that this interesting study has limitations that relativise the results and their interpretation. Removing these limitations could strengthen the conclusions and reinforce the message of the study. All unanswered questions need to be clarified before readers can uncritically accept the study's conclusions. In patients with necrotizing fasciitis of the legs, severe heart failure and anticoagulation

with dabigatran, debridement under spinal anaesthesia after antagonisation with idarucizumab should be considered.

Finsterer J¹, PhD

Zarrouk S², PhD

¹Neurological Department, Neurology and Neurophysiology Center, Vienna, Austria

²Department of Genomic Platform, University of Tunis El Manar, Tunis, Tunisia

REFERENCES

1. Faris MK, Norazrin MA, Izzuddin MS, Thiru MK. Dabigatran-induced Enterococcus Necrotizing Fasciitis in Medically Unfit Patient with Successful Conservative Treatment Outcome: A Case Report. *Malays Orthop J.* 2024; 18(3): 80-3. doi: 10.5704/MOJ.2411.012
2. Wallace HA, Perera TB. Necrotizing Fasciitis. 2023 Feb 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
3. Mitchell A, Williams A, Dzendrowskyj P. Necrotising fasciitis: an 8.5-year retrospective case review in a New Zealand intensive care unit. *Crit Care Resusc.* 2011; 13(4): 232-7. doi: 10.1016/S1441-2772(23)01599-5
4. Howie WO. Anesthetic implications of necrotizing fasciitis. *AANA J.* 2003; 71(1): 37-40.

Cite this article:

Finsterer J, Zarrouk S. In Patients not Suitable for Generalised Anaesthesia, Surgery for Necrotising Fasciitis under Spinal Anaesthesia should be Considered. *Malays Orthop J.* 2025; 19(1): 133-5. doi: 10.5704/MOJ.2503.019

AUTHORS' REPLY TO THE LETTERS TO THE EDITOR

We value the editorial board's detailed review of our case report and are pleased to address the concerns highlighted. We agree there is no direct evidence linking dabigatran to necrotizing fasciitis (NF). Our report aimed to highlight anticoagulation's potential role in exacerbating soft tissue haemorrhage, contributing to NF1. A more precise title, such as "Dabigatran-Associated Enterococcus Necrotizing Fasciitis in a Medically Unfit Patient," could help avoid potential misinterpretations.

NF was diagnosed clinically based on the rapid disease progression, including blackish discoloration, haemorrhagic bullae, and systemic sepsis^{1,2}. The LRINEC score of 8, though not mentioned initially, strongly supported the

diagnosis. While magnetic resonance imaging (MRI) is a valuable diagnostic tool in well-equipped centres, its utility is most effective in cases with atypical or mild presentations. MRI or biopsy was not pursued to avoid delays, as the presentation was unequivocal.

The infection route remains uncertain. The absence of trauma or wounds, coupled with anticoagulation-induced hematomas, likely provided a nidus for bacterial growth. *Enterococcus* sp., a gut commensal, may have originated from gastrointestinal translocation or hematogenous spread².

Given the patient's critical condition, severe heart failure (ejection fraction of 7%), coagulopathy, and multiorgan dysfunction, surgery under spinal anaesthesia, even with Idarucizumab reversal, posed substantial risks. Additionally, Idarucizumab was not readily available. A multidisciplinary team concluded, with patient and family agreement, that conservative management was the safest course.

Dabigatran was prescribed for left ventricular mural thrombus prophylaxis following an echocardiogram identifying severe heart failure with global hypokinesia. Admission findings of prolonged aPTT and elevated INR indicated excessive anticoagulation, exacerbated by the sepsis-related coagulopathy.

The patient had dilated cardiomyopathy due to long-standing hypertension, accompanied by hyperlipidaemia and smoking, with a hallmark severely reduced ejection fraction. He was on beta-blockers, ACE inhibitors, and dabigatran at admission.

The patient initially required resuscitation due to septic shock, which was secondary to the NF. Elevated CRP levels further supported the diagnosis of systemic inflammation and sepsis which also helped in monitoring the progression of the disease and the patient's recovery during treatment³.

In conclusion, we recognise the study's limitations and appreciate the suggestions to strengthen its conclusions. However, we maintain that conservative management was appropriate given the patient's high perioperative risk. We trust this explanation provides further clarity on our approach and the complexities involved in this case.

REFERENCES

1. Wallace HA, Perera TB. Necrotizing Fasciitis. 2023 Feb 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
2. Faris MK, Norazrin MA, Izzuddin MS, Thiru MK. Dabigatran-induced Enterococcus Necrotizing Fasciitis in Medically Unfit Patient with Successful Conservative

Treatment Outcome: A Case Report. *Malays Orthop J.* 2024; 18(3): 80-3. doi: 10.5704/MOJ.2411.012

3. Anush MM, Ashok VK, Sarma RI, Pillai SK. Role of C-reactive Protein as an Indicator for Determining the Outcome of Sepsis. *Indian J Crit Care Med.* 2019; 23(1): 11-4. doi: 10.5005/jp-journals-10071-23105

Ahmad Faris Mohd Khairuddin
Muhamad Izzuddin Mohd Sharif
Mohamad Norazrin Mohd Abas
Thiru Kumaran Mootha Kumaran

Department of Orthopaedic Surgery, Miri Hospital, Miri, Sarawak